Nancy E. Denyes Krueger
Net Worth
Last updated:
What is Nancy E. Denyes Krueger net worth?
The estimated net worth of Ms. Nancy E. Denyes Krueger is at least $2,862,840 as of 5 Feb 2024. She has received compensation worth at least $2,862,840 in aTyr Pharma, Inc..
What is the salary of Nancy E. Denyes Krueger?
Ms. Nancy E. Denyes Krueger salary is $477,140 per year as Gen. Counsel & Corporation Sec. in aTyr Pharma, Inc..
How old is Nancy E. Denyes Krueger?
Ms. Nancy E. Denyes Krueger is 57 years old, born in 1968.
What stocks does Nancy E. Denyes Krueger currently own?
As insider, Ms. Nancy E. Denyes Krueger owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| aTyr Pharma, Inc. (LIFE) | Gen. Counsel & Corporation Sec. | 2,735 | $0 | $0 |
What does aTyr Pharma, Inc. do?
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Nancy E. Denyes Krueger insider trading
aTyr Pharma, Inc.
Ms. Nancy E. Denyes Krueger has made 2 insider trades between 2019-2024, according to the Form 4 filled with the SEC.
The largest trade she's ever made was exercising 12,500 units of LIFE stock on 16 May 2019. As of 5 Feb 2024 she still owns at least 2,735 units of LIFE stock.
aTyr Pharma key executives
aTyr Pharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Sanjay S. Shukla (53) Pres, Chief Executive Officer & Director
- Ms. Jill M. Broadfoot (63) Chief Financial Officer
- Ms. Nancy E. Denyes Krueger (57) Gen. Counsel & Corporation Sec.